Search Results - "YANG, James"

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations by Paik, Paul K, Felip, Enriqueta, Veillon, Remi, Sakai, Hiroshi, Cortot, Alexis B, Garassino, Marina C, Mazieres, Julien, Viteri, Santiago, Senellart, Helene, Van Meerbeeck, Jan, Raskin, Jo, Reinmuth, Niels, Conte, Pierfranco, Kowalski, Dariusz, Cho, Byoung Chul, Patel, Jyoti D, Horn, Leora, Griesinger, Frank, Han, Ji-Youn, Kim, Young-Chul, Chang, Gee-Chen, Tsai, Chen-Liang, Yang, James C.-H, Chen, Yuh-Min, Smit, Egbert F, van der Wekken, Anthonie J, Kato, Terufumi, Juraeva, Dilafruz, Stroh, Christopher, Bruns, Rolf, Straub, Josef, Johne, Andreas, Scheele, Jürgen, Heymach, John V, Le, Xiuning

“…In a study involving patients with non–small-cell lung cancer with a MET exon 14 skipping mutation, the use of tepotinib (a selective MET inhibitor) was…”
Get full text

First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases by Schuler, Martin, Wu, Yi-Long, Hirsh, Vera, O'Byrne, Kenneth, Yamamoto, Nobuyuki, Mok, Tony, Popat, Sanjay, Sequist, Lecia V, Massey, Dan, Zazulina, Victoria, Yang, James C-H

“…Metastatic spread to the brain is common in patients with non-small cell lung cancer (NSCLC), but these patients are generally excluded from prospective…”
Get more information

Landscape of Tumor Antigens in T Cell Immunotherapy by Ilyas, Sadia, Yang, James C

“…Cancer immunotherapy is a rapidly evolving field that exploits T cell responses to tumor-associated Ags to induce tumor rejection. Molecular identification of…”
Get full text

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer by Ramalingam, Suresh S, Yang, James C-H, Lee, Chee Khoon, Kurata, Takayasu, Kim, Dong-Wan, John, Thomas, Nogami, Naoyuki, Ohe, Yuichiro, Mann, Helen, Rukazenkov, Yuri, Ghiorghiu, Serban, Stetson, Daniel, Markovets, Aleksandra, Barrett, J Carl, Thress, Kenneth S, Jänne, Pasi A

“…Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety…”
Get full text

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial by Camidge, D Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C H, Han, Ji-Youn, Hochmair, Maximilian J, Lee, Ki Hyeong, Delmonte, Angelo, García Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander, Gettinger, Scott N, Tiseo, Marcello, Lin, Huamao M, Gupta, Neeraj, Hanley, Michael J, Ni, Quanhong, Zhang, Pingkuan, Popat, Sanjay

“…Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related…”
Get full text

Toxicities of Immunotherapy for the Practitioner by Weber, Jeffrey S, Yang, James C, Atkins, Michael B, Disis, Mary L

“…The toxicities of immunotherapy for cancer are as diverse as the type of treatments that have been devised. These range from cytokine therapies that induce…”
Get full text

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis by Lee, Chee Khoon, Man, Johnathan, Lord, Sally, Links, Matthew, Gebski, Val, Mok, Tony, Yang, James Chih-Hsin

“…We performed a meta-analysis to assess the role of immune checkpoint inhibitors as second-line therapy in EGFR-mutant advanced NSCLC. Randomized trials…”
Get more information

Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial by Camidge, D Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C H, Han, Ji-Youn, Hochmair, Maximilian J, Lee, Ki Hyeong, Delmonte, Angelo, Garcia Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander I, Gettinger, Scott N, Tiseo, Marcello, Lin, Huamao M, Liu, Yuyin, Vranceanu, Florin, Niu, Huifeng, Zhang, Pingkuan, Popat, Sanjay

“…In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L), which is a study of brigatinib in ALK inhibitor-naive advanced…”
Get more information

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study by Yang, James C H, Kim, Sang-We, Kim, Dong-Wan, Lee, Jong-Seok, Cho, Byoung Chul, Ahn, Jin-Seok, Lee, Dae H, Kim, Tae Min, Goldman, Jonathan W, Natale, Ronald B, Brown, Andrew P, Collins, Barbara, Chmielecki, Juliann, Vishwanathan, Karthick, Mendoza-Naranjo, Ariadna, Ahn, Myung-Ju

“…In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in…”
Get full text

Systemic Administration of Exosomes Released from Mesenchymal Stromal Cells Promote Functional Recovery and Neurovascular Plasticity After Stroke in Rats by Xin, Hongqi, Li, Yi, Cui, Yisheng, Yang, James J, Zhang, Zheng Gang, Chopp, Michael

“…Here, for the first time, we test a novel hypothesis that systemic treatment of stroke with exosomes derived from multipotent mesenchymal stromal cells (MSCs)…”
Get full text

Efficient matrix profile computation with Euclidean distance using Eigen transformation: Performance evaluation based on beat‐to‐beat interval (BBI) data by Yang, James J., Buu, Anne

“…The matrix profile serves as a fundamental tool to provide insights into similar patterns within time series. Existing matrix profile algorithms have been…”
Get full text

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 by Yang, James C-H, Prof, Sequist, Lecia V, MD, Geater, Sarayut Lucien, MD, Tsai, Chun-Ming, Prof, Mok, Tony Shu Kam, Prof, Schuler, Martin, Prof, Yamamoto, Nobuyuki, Prof, Yu, Chong-Jen, Prof, Ou, Sai-Hong I, MD, Zhou, Caicun, Prof, Massey, Daniel, MSc, Zazulina, Victoria, MD, Wu, Yi-Long, Prof

“…Summary Background Most patients with non-small-cell lung cancer tumours that have EGFR mutations have deletion mutations in exon 19 or the Leu858Arg point…”
Get full text

Precision Management of Advanced Non-Small Cell Lung Cancer by Yang, Ching-Yao, Yang, James Chih-Hsin, Yang, Pan-Chyr

“…The rapid evolution of treatment for advanced lung cancer is a story of how scientists have struggled to move from nonselective cytotoxic chemotherapy to…”
Get full text

Adoptive T-Cell Therapy for Cancer by Yang, James C, Rosenberg, Steven A

“…Recent developments have demonstrated that immunotherapies are capable of achieving durable antitumor responses in patients with metastatic cancer. One…”
Get more information

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer by Jenkins, Suzanne, Yang, James C-H, Ramalingam, Suresh S, Yu, Karen, Patel, Sabina, Weston, Susie, Hodge, Rachel, Cantarini, Mireille, Jänne, Pasi A, Mitsudomi, Tetsuya, Goss, Glenwood D

“…Tumor biopsies for detecting EGFR mutations in advanced NSCLC are invasive, costly, and not always feasible for patients with late-stage disease. The clinical…”
Get more information

Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC by Planchard, David, Jänne, Pasi A, Cheng, Ying, Yang, James C-H, Yanagitani, Noriko, Kim, Sang-We, Sugawara, Shunichi, Yu, Yan, Fan, Yun, Geater, Sarayut L, Laktionov, Konstantin, Lee, Chee K, Valdiviezo, Natalia, Ahmed, Samreen, Maurel, Jean-Marc, Andrasina, Igor, Goldman, Jonathan, Ghiorghiu, Dana, Rukazenkov, Yuri, Todd, Alex, Kobayashi, Kunihiko

“…Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and T790M…”
Get full text

Brain insulin resistance and the therapeutic value of insulin and insulin-sensitizing drugs in Alzheimer’s disease neuropathology by Yang, James J.

“…The incidence of Alzheimer’s disease (AD) is significantly higher in people with diabetes. Insulin and insulin receptor (IR) signaling intermediates are…”
Get full text

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases by Yang, James Chih-Hsin, Schuler, Martin, Popat, Sanjay, Miura, Satoru, Heeke, Simon, Park, Keunchil, Märten, Angela, Kim, Edward S

“…Limited clinical data are available regarding the efficacy of EGFR tyrosine kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR…”
Get more information

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study by Langer, Corey J, Dr Prof, Gadgeel, Shirish M, Prof, Borghaei, Hossein, DO, Papadimitrakopoulou, Vassiliki A, Prof, Patnaik, Amita, MD, Powell, Steven F, MD, Gentzler, Ryan D, MD, Martins, Renato G, Prof, Stevenson, James P, MD, Jalal, Shadia I, MBBS, Panwalkar, Amit, MD, Yang, James Chih-Hsin, Prof, Gubens, Matthew, MD, Sequist, Lecia V, MD, Awad, Mark M, MD, Fiore, Joseph, PharmD, Ge, Yang, PhD, Raftopoulos, Harry, MD, Gandhi, Leena, Prof

“…Summary Background Limited evidence exists to show that adding a third agent to platinum-doublet chemotherapy improves efficacy in the first-line advanced…”
Get full text

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies by Ahn, Myung‐Ju, Tsai, Chun‐Ming, Shepherd, Frances A., Bazhenova, Lyudmila, Sequist, Lecia V., Hida, Toyoaki, Yang, James C. H., Ramalingam, Suresh S., Mitsudomi, Tetsuya, Jänne, Pasi A., Mann, Helen, Cantarini, Mireille, Goss, Glenwood

“…Background Osimertinib is a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is selective for both…”
Get full text